Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Expanding ADC Therapeutic Index Through Site-Specific Bioconjugation & Tumor Selective Payload Release & Activation

Expanding ADC Therapeutic Index Through Site-Specific Bioconjugation & Tumor Selective Payload Release & Activation

11:30 am - Tuesday 13th October 2026

Discussing how site specific ConjuAll platform enables discrete DAR ADCs with circulation stable bioconjugation
Leveraging proprietary beta glucuronidase technology to enable unprecedented preclinical therapeutic indexes through tumor selective release and payload activation
Assessing early clinical safety and efficacy across payload classes to validate the LCB platform

Speakers:

Stephen Slocum

Stephen Slocum

Director - Drug Development, Project Lead

LigaChem Biosciences